Dormonoct is a prescription medicine used for its hypnotic (sleep-inducing) properties to address significant sleep disturbances. Its therapeutic application focuses strictly on providing short-term symptomatic relief when sleeplessness is severe, debilitating, or associated with intense distress.

Managing Severe and Debilitating Insomnia

Dormonoct is commonly used across conditions presenting with acute episodes of sleeplessness. It is applied in clinical settings that involve acute or unstable symptom patterns where additional symptomatic support is needed to address pronounced manifestations of insomnia. The key therapeutic domains include the short-term treatment of insomnia, pre-operative sleep disturbances, and managing sleep issues in geriatric patients.

This supportive use contributes to improved comfort during periods of heightened symptoms and helps patients cope more steadily with difficult episodes. This usage aligns with the clinical understanding that:

“The medication is generally reserved for situations where the sleep disorder is classified as severe or significantly debilitating, and provides short-term symptomatic assistance.”

Addressing Sleep Initiation and Maintenance Difficulties

The medication is relevant for managing symptoms that interfere with daily comfort, specifically the difficulty falling asleep (sleep onset disturbance) and the inability to maintain sleep due to frequent or early awakening. This therapeutic use plays a role in managing these symptom clusters. Its role is to facilitate the temporary achievement of rest, which provides supportive relief and assists with maintaining functional stability.

---

Quick Fact: Relief for Sleep Onset Difficulty

Dormonoct is commonly used to help patients experiencing symptoms related to difficulty initiating sleep, to help address difficulty falling asleep and promote temporary sleep stability.

---

Regulatory References

1. South African Health Products Regulatory Authority (SAHPRA) product information

Dormonoct eligibility is strictly defined by regulatory authorities through specific population exclusions and restrictions based on physiological status, comorbidities, and age.

---

Absolute Contraindications

Dormonoct is formally contraindicated and must not be used by patients with known hypersensitivity to clobazam or its components. Use is also strictly prohibited in patients with acute severe respiratory insufficiency, Myasthenia Gravis, severe hepatic dysfunction (severe liver disease), and severe sleep apnea syndrome. The medicine is also contraindicated for breastfeeding women and during the first trimester of pregnancy.

---

Age and Organ-Function Restrictions

Pediatric patients under 2 years of age are excluded because safety and efficacy have not been established. Use is often restricted in children between 6 months and 3 years. Elderly patients require a dosage adjustment due to altered metabolism.

Eligibility is also conditional on organ function: patients with mild to moderate hepatic impairment and individuals identified as CYP2C19 Poor Metabolizers require a dosage adjustment. Regulatory documents note no experience with use in patients with severe renal impairment.

Dormonoct Interactions with other medicines and products

The interaction profile for Dormonoct (Clobazam) is categorized based on its effects on central nervous system (CNS) function and its involvement with the body’s metabolic enzymes, as documented in regulatory information.

Pharmacodynamic Interactions

Co-administration with other CNS Depressants leads to potentiation of sedation and CNS depression. The co-use of Dormonoct with Opioids is subject to the highest restriction level, as documented by a Boxed Warning, due to the severe risk of profound sedation, respiratory depression, coma, and death.

Pharmacokinetic Interactions

Co-use with Strong or Moderate CYP2C19 Inhibitors (e.g., fluconazole) increases the plasma levels of Dormonoct’s active metabolite, N-desmethylclobazam, which may require adjustment. Conversely, the active metabolite is a moderate inhibitor of CYP2D6, which increases the exposure of co-administered medicines that are CYP2D6 substrates. Dormonoct may also cause Hormonal Contraceptives to not work well, indicating a risk of reduced efficacy.

Substance and Population-Specific Interactions

Alcohol consumption is documented to increase Clobazam blood levels by approximately 50%. Furthermore, official prescribing information notes that individuals who are CYP2C19 poor metabolizers and those with hepatic impairment require a lower starting dosage due to altered drug processing.

How Dormonoct Works

Dormonoct acts as a non-benzodiazepine agent. Its primary molecular target is the gamma-aminobutyric acid type A ( GABA A) receptor complex, a ligand-gated ion channel expressed extensively throughout the central nervous system (CNS). Dormonoct functions as a positive allosteric modulator, binding at a specific omega1 subtype site on the receptor that is distinct from the primary GABA binding site. This allosteric interaction enhances the effect of the inhibitory neurotransmitter GABA.

Specifically, the binding of Dormonoct increases the frequency of chloride ion ( Cl^-) channel opening upon GABA activation. The resulting rapid influx of negatively charged Cl^- ions across the neuronal cell membrane drives the hyperpolarization of the post-synaptic neuron. This hyperpolarization decreases the responsiveness of the neuron to excitatory input, leading to a generalized reduction in CNS excitability. This systemic dampening of excitatory circuits modulates the sleep-wake cycle via known pharmacological mechanisms.

Dormonoct is administered solely via the oral route as a tablet, with the use protocol strictly defined. The medication is intended for a single daily dose, which must be taken approximately half an hour before the intended time of sleep, typically at bedtime. The tablet must be swallowed whole with a sufficient amount of liquid and should not be chewed.

The standard daily dosing regimen for adults ranges from 1 mg to 2 mg. The use of the 2 mg dose is typically reserved for situations of severe, persistent sleeplessness, such as in patients previously managed with benzodiazepines, and the prescribed maximum dosage must not be exceeded. For specific patient groups, including elderly or debilitated individuals, the protocol requires initiation with a lower starting dose, specifically ranging from 0.5 mg to 1.0 mg.

Usage patterns for this medication are strictly governed by duration constraints. Treatment should be kept as short as possible, generally lasting only a few days to two weeks. The total course of treatment, including the mandatory discontinuation phase, must not exceed four weeks. A gradual reduction in the dosage, or tapering, is a required procedural step when ending use, ensuring the full protocol is followed within the maximum time limit.

Research Evidence / Overview of Studies for Dormonoct

Evidence for Use in Severe Sleep Disturbances

The research involving Clobazam, the active ingredient in Dormonoct, was conducted in patients experiencing sleep difficulties. The evidence base includes older, controlled trials (RCTs) that compared the compound to an inactive treatment (placebo) or other sleep medications. The compound was observed in research exploring how sleep patterns were measured when individuals are dealing with difficulties both falling asleep (onset) and staying asleep (maintenance).

Research measured outcomes such as patient-reported outcomes describing perceived discomfort related to sleep, and specific metrics like the time it took for a patient to fall asleep (sleep onset latency) and the total duration a patient slept during the observation period. Furthermore, research examined outcomes reflecting daily functioning or activity level, such as psychomotor performance the following morning, to see if use was associated with observed changes. While evidence describes patterns measured during the study period, the findings were mixed across different studies.

Long-Term Research and Follow-up Duration

The current research landscape for the compound's role in addressing sleep difficulties is defined by studies conducted over short and intermediate time intervals. Follow-up durations were limited, often extending only to a few weeks, which is relevant in trials assessing short-term or episodic symptom patterns. Therefore, the data indicate patterns related to temporary physiological change and were not used for chronic management.

There is limited information for long-term outcomes, and long-term effects are not fully established. Research so far indicates that studies do not fully characterize the durability of any changes measured over many months of use.

Evidence in Special Populations

Studies were evaluated in specific populations. Studies were evaluated in older adults, where the compound was observed and monitored. Furthermore, studies were observed in patients with certain co-existing neurological conditions where sleep was monitored as an exploratory outcome. This means evidence derived from settings with varying symptom burdens helps contextualize how patients reported their experience. However, subgroup findings are uncertain because the results apply only to the populations studied.

What is Still Uncertain About Dormonoct Research

Several limitations and uncertainties exist in the current evidence landscape for Dormonoct. One key limitation is that many of the direct efficacy studies are older; the evidence quality varies across studies, and there is limited information for long-term outcomes regarding contemporary, large-scale controlled trials focused solely on primary insomnia. Furthermore, comparative evidence is lacking, and sample sizes were modest in the studies observing specific sleep architecture parameters. Evidence highlights what is known—and what is still uncertain—about the compound’s use in short-term research.

Key Studies & References

1. Dormonoct (Clobazam 10 mg Tablet) Product Information

Common questions about Dormonoct (FAQ)

---

Q: What is the main purpose of Dormonoct?

According to official regulatory documents, the main purpose of Dormonoct is the short-term treatment of moderately-severe insomnia. This may include difficulties with falling asleep or experiencing frequent waking during the night. Official information consistently restricts its use to short periods, generally not exceeding four weeks.

Q: Is Dormonoct a treatment for all types of insomnia?

Dormonoct is specifically indicated for the short-term management of moderately-severe insomnia that is disabling or causing the patient severe distress. Hypnotic medicines are not generally recommended for chronic insomnia but rather for short periods of use to address severe sleeplessness.

Q: Is it true that Dormonoct is not available in the United States?

Regulatory data indicates that the active ingredient in Dormonoct, known as Loprazolam, is not an FDA-approved drug for marketing in the United States. Availability of the drug is determined by the regulatory body in each country or region.

Q: What is the chemical name for the active ingredient in Dormonoct?

The active substance in the Dormonoct tablet is known chemically as Loprazolam. This is the active compound used to achieve the drug’s intended effects on the central nervous system.

Q: What are the most common side effects reported with Dormonoct?

The official product information lists commonly reported side effects, which include headache, nausea, general drowsiness, dizziness, and unsteadiness (ataxia). These effects are typically observed when treatment is initiated.

Q: Is feeling 'groggy' or drowsy the next morning a common side effect of Dormonoct?

Next-day effects such as persistent drowsiness, dizziness, and unsteadiness may occur. This is more likely to be experienced by sensitive patients or when use is associated with a higher dose.

Q: Can Dormonoct cause memory problems or forgetfulness?

Official documentation notes that side effects may include impaired concentration and loss of memory, which is known as anterograde amnesia. The potential risk of this side effect may increase with higher doses.

Q: Are there any rare but serious side effects associated with Dormonoct use?

Rare adverse effects have been reported, which may include paradoxical reactions such as aggressive outbursts, confusion, excitement, hypotension, and the uncovering of depression with suicidal tendencies.

Q: Can Dormonoct potentially cause increased anxiety or 'paradoxical' reactions?

Yes, paradoxical reactions, which are responses opposite to the expected effect, have been reported in the official safety data. These can include excitement, agitation, or even an increase in anxiety, although they are considered rare.

Q: What is the average elimination half-life of Dormonoct in healthy adults?

Pharmacokinetic data from regulatory bodies indicates that the average elimination half-life of the active ingredient, Loprazolam, typically ranges from approximately 5 to 20 hours in healthy adults. This pharmacokinetic measure describes the rate at which the substance is cleared from the body.

Q: Is there a risk of developing tolerance to Dormonoct with continued use?

The use of hypnotic drugs like Dormonoct carries a risk of developing tolerance. Tolerance is a condition where the drug’s effectiveness is reduced after it has been taken repeatedly for a sustained period.

Q: What are the signs of physical dependence related to Dormonoct?

Dependence is indicated by the presence of withdrawal symptoms when use is discontinued. Official guidance states that the risk of developing dependence increases with both the duration and the dosage of the treatment.

Q: Does Dormonoct have a risk of causing rebound insomnia when treatment is stopped?

Yes, the discontinuation of treatment may result in a temporary condition known as rebound insomnia. This describes the recurrence of a more severe form of sleeplessness than the one initially treated before use.

Q: Can patients with severe breathing problems safely use Dormonoct?

Official product information states that Dormonoct is contraindicated in individuals with severe respiratory insufficiency, acute pulmonary insufficiency, or sleep apnoea syndrome. This is due to the risk of respiratory depression associated with CNS depressants.

Q: Is Dormonoct suitable for use by children or adolescents?

Regulatory documents advise that benzodiazepines and related hypnotics should generally not be used in children or adolescents. Official guidance indicates that use in this population is determined following a careful medical assessment of therapeutic need.

Q: What are the official warnings regarding Dormonoct and misuse?

Loprazolam is regulated as a Schedule IV controlled substance due to the recognized potential for abuse and the development of both physical and psychological dependence. Regulatory guidance specifies restrictions on its use and duration.

Q: What are the potential effects of Dormonoct if used during pregnancy or while breastfeeding?

Use during pregnancy is generally advised against due to potential risks to the fetus. Official data indicates the drug passes into breast milk, and it may cause adverse effects in the infant, such as excessive sedation or difficulty feeding.

Q: Is there an increased risk of falls for elderly patients taking Dormonoct?

Regulatory warnings note that Dormonoct can cause drowsiness and a reduction in consciousness. For elderly patients, this effect may lead to an increased risk of falls and potentially severe resulting injuries.

Q: Is Dormonoct a controlled medicine, and what does that classification mean?

The drug is classified as a Schedule IV controlled substance. This classification indicates the drug is subject to strict governmental regulation and monitoring due to its potential for abuse or dependence.

Q: Can Dormonoct affect a person's ability to drive or operate machinery the next day?

Official regulatory warnings explicitly state that Dormonoct impairs cognitive function and can affect a patient's ability to drive safely or use heavy machinery. This is due to risks of prolonged drowsiness, sedation, and impaired concentration.

Q: What specific type of medicine is Dormonoct classified as?

Dormonoct is part of the imidazobenzodiazepine drug group and is pharmacologically classified as a hypnotic or sedative. This classification defines its primary action in helping to induce or maintain sleep.

Q: What medical conditions would make a person ineligible to use Dormonoct?

The official contraindications for Dormonoct include a known hypersensitivity to benzodiazepines, myasthenia gravis, sleep apnoea syndrome, and severe respiratory conditions, including acute pulmonary insufficiency.

Q: What is the importance of the black box warnings associated with this class of drug?

A Boxed Warning is the strongest safety statement issued by regulatory bodies. For this drug, the warning specifically highlights the severe risk of profound sedation, severe respiratory depression, coma, and death when Dormonoct is used concomitantly with opioids.

Q: Can Dormonoct cause slurred speech or impaired coordination?

The official safety documentation lists side effects such as muscular weakness, unsteadiness, and ataxia (a loss of full control of body movements). These effects relate to the drug’s function as a central nervous system depressant.

Q: How does Dormonoct affect the body's sleep cycle?

The drug acts by enhancing the activity of the inhibitory neurotransmitter GABA in the brain. This enhancement reduces the general excitability of the central nervous system, which in turn modulates the sleep-wake cycle.

Q: Is it necessary to plan for a full night's sleep when taking Dormonoct?

Due to the risk of experiencing next-day impairment and sedation, sufficient time is generally necessary to allow the drug's primary effects to dissipate before engaging in daily activities.

Q: Is it safe to take Dormonoct with common over-the-counter cold medicines?

Official warnings exist regarding the combined use of Dormonoct with other central nervous system (CNS) depressants. Certain over-the-counter cold and allergy medicines contain ingredients that also depress the CNS, which can lead to enhanced sedative effects.

Q: Can Dormonoct be used to treat anxiety disorders as well as insomnia?

While the drug possesses anxiolytic (anxiety-reducing) properties, its official therapeutic indication is strictly limited to the short-term treatment of insomnia as defined by regulatory bodies.

Q: Is it true that Dormonoct should not be used alone to treat depression?

Yes, official prescribing information states that Dormonoct should not be used as monotherapy (the sole treatment) for depression. This restriction also applies to anxiety that may be associated with depression.

Q: Are headaches a commonly reported symptom when withdrawing from Dormonoct?

Headache is listed as one of the commonly reported symptoms that may be experienced during the withdrawal phase following the discontinuation of Dormonoct. This is part of the broader range of discontinuation effects.

Q: Can Dormonoct cause a feeling of detachment or derealization?

Regulatory data notes that discontinuation or withdrawal symptoms may include feelings of unreality or depersonalization. Depersonalization is described as a persistent feeling of being detached from one's own body or mental processes.

Q: Is it possible to have an allergic reaction to Dormonoct?

Yes, Dormonoct is strictly contraindicated in individuals with a known hypersensitivity (allergic reaction) to the active ingredient, Loprazolam, or to other medicines in the benzodiazepine class.

Q: What is the risk of using Dormonoct if a person has a history of substance abuse?

Official warnings state that the risk of dependence on Dormonoct is significantly higher in patients with a prior history of alcohol or drug abuse. Due caution is required when the drug is used in this specific population.

How to Store and Dispose of Dormonoct?

Official regulatory guidelines define specific conditions for the storage and disposal of this medicine, maintaining its integrity and ensuring safety.

Storage Requirements

Condition	Requirement	Constraint
Temperature	Store at room temperature	Do not exceed 25 C; Keep from freezing
Environment	Store in a closed, original container	Protect from moisture, heat, and direct light
Safety	Mandatory requirement	Keep out of the sight and reach of children

Disposal Instructions

When the product is expired or no longer needed, it must be disposed of safely according to local regulations. The official, preferred method is through a drug take-back program.

It is prohibited to throw the tablets directly into household trash or to dispose of them in wastewater. If a take-back program is unavailable, follow specific guidelines to mix the medicine with an undesirable substance before discarding in the trash.